GeoVax Labs, Inc. — Q3 2016 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2016. GeoVax is a clinical-stage vaccine developer focused on HIV, hemorrhagic fever viruses, Zika, cancer immunotherapy, and chronic hepatitis B. It had no approved products or commercial product revenue; reported revenue was from government grants and contracts.
Financial results
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Grant revenue | $440,106 | $93,130 | $653,986 | $268,028 |
| Research and development | $683,939 | $378,521 | $1,519,519 | $1,166,803 |
| General and administrative | $220,707 | $335,932 | $1,472,030 | $1,102,262 |
| Net loss | $464,200 | $619,899 | $2,336,314 | $1,996,556 |
| Loss per common share | $0.01 | $0.02 | $0.06 | $0.06 |
Grant revenue is recognized as related reimbursable costs are incurred, so it generally offsets a portion of expenses; conventional gross margin is not presented. Nine-month operating cash use was $1,577,678, versus $1,944,573 in 2015. Cash and equivalents were $511,096 at September 30, down from $1,060,348 at year-end 2015; working capital was $349,569, versus $1,109,985. Total assets were $675,191 and current liabilities $252,589. The filing reports no long-term debt or committed credit line.
Changes and notable items
- Q3 net loss narrowed year over year, while the nine-month net loss increased. Nine-month R&D rose about $353,000; G&A rose about $370,000, including $484,829 of noncash warrant-modification expense (versus none in 2015).
- Warrant exercises provided $1,028,426 in financing cash during the first nine months. GeoVax issued 15,821,920 common shares from warrant exercises and 1,400,000 shares from preferred-stock conversions. Common shares outstanding increased to 49,172,733 from 31,950,813 at year-end 2015.
- As of September 30, 40,620,237 warrants remained outstanding; preferred stock, warrants, and equity plans together reserved 76,089,142 common shares for potential issuance.
- Noncancellable lease and other firm purchase obligations totaled approximately $495,000. About $305,000 of purchase commitments were expected to be reimbursed through government grants.
Outlook, risks, and contingencies
- Management expected available cash and government funding to support planned operations into the first quarter of 2017, but said substantial doubt remained about the company’s ability to continue as a going concern beyond that point. Additional funding was necessary and might not be available on favorable terms or at all; absent funding, programs or overhead could be cut.
- GeoVax reported $680,419 in approved grant and contract funds available at September 30, expected to be recognized through July 2017. NIH funding for an HIV vaccine Phase 1 trial was expected, with enrollment anticipated to begin in January 2017. NIH awarded a production contract with a $199,442 base award and $7.6 million in additional options; those options were not assured funding.
- Management expected R&D costs to increase as programs advance. Clinical, regulatory, funding, and product-development outcomes are uncertain, and the company may never generate significant product revenue.
- The filing reported no material change to previously disclosed risk factors, no legal proceedings, and effective disclosure controls. The financial statements are unaudited, and interim results are not necessarily indicative of full-year results.
Important facts for investors to verify
- Subsequent financing, cash runway, and whether funding was secured to continue operations beyond Q1 2017.
- Actual NIH grant reimbursements and whether NIH exercised the development options under the vaccine production contract.
- Clinical trial timing and progress, particularly the anticipated GOVX-B11 trial, and the availability of external trial support.
- Potential dilution from outstanding warrants, convertible preferred stock, and equity-plan reserves.
- Whether the large warrant-modification expense is nonrecurring and how future operating costs compare with available grant funding.